Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline

Abstract

Cabergoline, typically dosed for the long-term treatment of hyperprolactinemia or acromegaly, appears not to be associated with an increased risk of fibrotic adverse events.